Menu
Recruiting NCT06116032

Immune Profiling for Cancer Immunotherapy Response

— Observational Cancer Tumor, Solid Hematologic Malignancy Blood Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Methylation Cytometry.
Who it may be relevant to
Registry conditions: Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Interventions

  • Diagnostic test Methylation Cytometry
    Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.

Primary outcome measures

  • Response to therapy [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
  • Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion criteria

  • Pregnant women/fetuses/neonates
  • Prisoners
  • Decision-impaired individuals

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Dartmouth-Hitchcock Medical Center — Lebanon

Identifiers

NCT: NCT06116032 · Study02001227

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗